Clinician and full professor at the Shanghai University of Medicine and Health. Full time chief associate clinician at Shanghai Renji University Hospital of Jiaotong. Training at Harvard Medical School affiliated hospitals (Mass General. Beth Israel, Brigham's and Dana Farber), Columbia University Presbyterian Hospital and Basel 

University Hospital. Specialist in Internal Medicine and Medical Oncology. Research focus on healthy longevity medicine, Artificial Intelligence (AI) and digital health with a research focus on oncology, preventative and precision medicine, biogerontology and geroncology.

Prof. Bischof spent a decade practicing medicine, lecturing at medical schools and performing clinic and translational research in New York, Shanghai and Basel, Switzerland. She has extensive experience in scientific research and clinical practice at the following well known and highly reputable institutions: Fudan Cancer Institute and Hospital, Shanghai; Zhongshan Hospital (Fudan University). Renji Hospital (Jiaotong University) and Shanghai East Hospital (Tongji University). Dr. Bischof has published over 180 peer-reviewed papers and is a frequent speaker at scientific and medical conferences. Known for an interest in preserving longevity, Dr. Bischof is well known for her excellent work in the field of medicine on an international and cross-cultural level. e.g. as a board member of the European Federation of Internal medicine. Swiss Society of Internal Medicine, Royal Society of Medicine and more.

Dr. Claudio Viecelli is a molecular and cellular biologist who received a PhD in muscle physiology from ETH Zurich. He demonstrated how ubiquitously available technologies (e.g., smartphones) can be leveraged to obtain mechano-biological descriptors of resistance exercise. These technologies can be used to monitor and personalize resistance exercise. He has published multiple reviews highlighting the importance of resistance exercise and its contributions to health and longevity, discussing the roles of resistance exercise descriptors and the influences of age, sex, and genetics.

After his PhD, he was a postdoctoral researcher at ETH Zurich, where he developed a motorized resistance exercise machine to examine the potential for personalizing resistance exercise. In 2024, he joined Keyoniq Switzerland AG as Chief Scientific Officer.

Dr. Christopher Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine. He completed a dual B.S. in Genetics & Biochemistry at University of Wisconsin-Madison (2001), a Ph.D. in Genetics from Yale University (2006), Post-doctoral Fellowship in Clinical Genetics at Yale Medical School (2009) while also serving as the first Visiting Fellow of Genomics, Ethics, and Law at the Information Society Project at Yale Law School (2006-2009). In 2010, he became an Assistant Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine, then promoted to Associate Professor in 2015, made the Director ofthe WorldQuant Initiative for Quantitative Prediction in 2017, and promoted to Full Professor in 2020. He also holds appointments at Tri-Institutional Program on Computational Biology and Medicine (Cornell, Memorial Sloan-Kettering Cancer Center and Rockefeller University), the Sandra and Edward Meyer Cancer Center, the Feil Family Brain and Mind Research Institute, (BMRI), and is an affiliate fellow of the Information Society Project (ISP) at Yale Law School, affiliate faculty of the Consortium for Space Genetics at Harvard Medical School, and a Core Faculty Member of New York Genome Center (NYGC). He was named as one of the “Brilliant Ten” Scientists by Popular Science, featured as a TEDMED speaker, and called “The Genius of Genetics” by 92Y. He has >350 peer-reviewed papers and scholarly works that have been featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by several U.S. District Courts and the U.S. Supreme Court. He is an inventor on five patents, co-creator of five FDA-authorized diagnostic tests, has co-founded 10 biotechnology companies, and 3 non-profits, and he serves as an advisor to 32 others.

Dr. Brian Kennedy is a Distinguished Professor in the Departments of Biochemistry and Physiology and serves as the Director of the Healthy Longevity Translational Research Programme and the Bia-Echo Asia Centre for Reproductive Longevity and Equality, Yong Loo Lin School of Medicine, National University Singapore. In addition, he is also the Director of the Centre for Healthy Longevity, National University Health System. Collectively, NUS ageing research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

Dr. Kennedy’s research has been focused on delineating mechanisms driving biological aging and identifying interventions that extend healthspan and lifespan. His work was instrumental in uncovering roles for Sirtuins and the mTOR pathway in regulating aging. More recently, he has also focused on aging biomarker development. 

From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointment in the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010, and at the Davis School of Gerontology at USC. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

Dr. Kennedy served as Co-Editor-In-Chief at Aging Cell from 2011-2021 and has a  long track record of collaboration with scientists in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014.